The role of clinical characteristics and pulmonary function testing in predicting risk of pneumothorax by CT-guided percutaneous core needle biopsy of the lung

Chunhai Li1, Dexiang Wang2, Fengxia Yang3, Yang Song4, Xuejuan Yu4, Bo Liu1, Haipeng Jia1 and Wei Zhou4*

Abstract

Background: We aim to analyze the risk factors for pneumothorax associated with computed tomography (CT)-guided percutaneous core needle biopsy (PCNB) of the lung. Whether the lung function characteristics are related to pneumothorax is unclear.

Methods: We retrospectively evaluated 343 patients who received CT-guided pulmonary PCNBs and underwent preoperative pulmonary function testing. Demographical, lesion-related, procedure-related features and histopathological diagnosis, as well as results of pulmonary function test were analyzed as risk factors of pneumothorax.

Results: Variables associated with higher rate of pneumothorax were location of lesion, presence of emphysema, and dwell time. The proportion of middle lobe, lingular, or lower lobe lesions in pneumothorax group (30/50, 60.0%) is higher than non-pneumothorax group (113/293, 38.6%). The incidence of emphysema in pneumothorax group was significantly higher than that in non-pneumothorax group (34.0% vs. 7.5%). Obstructive pulmonary function abnormalities, not restrictive, mixed ventilation function abnormalities and small airway dysfunction, correlated with pneumothorax. Multivariate logistic regression analysis showed lower location of lesion sampled and presence of emphysema were independent predictors of pneumothorax. Although dwell time, FEV1/FVC ratio, FEF50%, FEF75% and FEF25–75% were significantly correlated with pneumothorax on univariate analysis, these were not confirmed to be independent predictors.

Conclusions: Patients with obstructive pulmonary dysfunction have a higher risk of pneumothorax. Presence of emphysema was the most important predictor of pneumothorax, followed by location of lesion.
malignant diagnosis [3]. PCNB has become an important procedure to obtain enough specimens for further biological identification and molecular spectrum analysis in the individualized target therapy [4].

Pneumothorax is one of the most common complications of PCNB of the lung. Pooled pneumothorax rate for core biopsy was 25.3% (95% CI 22.2–28.6%) [1]. Previously reported common risk factors of pneumothorax for PCNBs included size, needle pleural angle, dwell time, emphysema, hyperinflation, lesion depth or intrapulmonary needle tract length, interactive breath-hold, fissure crossed, position [5–10]. The aim of this study was to investigate whether pre-procedural pulmonary function testing could help identify patients at high risk of complications. However, there is no clear clinical quantitative index of pulmonary function to estimate the risk of pneumothorax during needle biopsy. This study focused on the role of lung function in predicting the risk of pneumothorax caused by PCNB, as well as the common risk factors.

**Methods**

**Patients and data collection**

Three hundred and forty-three patients with pulmonary function testing have been retrospectively evaluated from 1110 consecutive patients who received CT-guided PCNBs of the lung between January 2018 and December 2019. Pulmonary function testing was performed within 7 days before PCNB. All the patients had received PCNBs for histopathological diagnosis of lung lesions in Qilu Hospital, Cheeloo College of Medicine, Shandong University, under consistent procedure. This single institutional retrospective study was approved by our hospital institutional review board (registration number: KYLL-202008-145) and complied with the Declaration of Helsinki and the ethical standards of the institutional research committee of Qilu Hospital, Cheeloo College of Medicine, Shandong University. Inclusion criteria also consisted of patients with normal electrocardiogram and with adequate hepatic, renal and hematological function. If patients were given acetylsalicylic acid, warfarin or low-molecular-weight heparin, they were required to suspend their medication 1 week before the procedure and monitor the prothrombin time. Platelet count should be ≥ 50 × 10^9/L for biopsy.

Patient records were anonymized and de-identified prior to analysis. Collected data included patient demographics (age, gender, smoking history, prior surgery, radiotherapy or chemotherapy), characteristics of target lesions (location, the size of the sampled lesions, adjacent pleura or chest wall invasion), and procedure-related information (patient position, needle puncture site, length of biopsy pathway, dwell time, needle-pleural angle, number of needle redirections and pleural planes traversed, and number of tissue samplings), results of pulmonary function test, procedure-related complications (pneumothorax, chest drainage catheter insertion, and pulmonary hemorrhage), and the histopathological diagnosis in all cases.

Middle lobe, lingular, and lower lobe lesions were categorized as “lower locations”; upper lobe lesions, as “upper locations” [11]. Lesion size was measured as the largest diameter of the sampled lesion in the previous CT images. The depth of the lesion was gauged as the length of the needle track from the punctured pleura to the edge of the lesion sampled. The needle-pleural angle was calculated on the transverse 3-mm section in the craniocaudal dimension, according to the method suggested by Ko et al. [6]. It was defined as the minimum angle formed by a line tangent to the pleura at the puncture point and a line drawn along the needle (Fig. 1) [6]. Pneumothorax was evaluated by CT scan after biopsy, as the largest separation between the visceral and parietal pleura. Less than or equal to 1 cm was categorized as “minor pneumothorax”; greater than 1 cm but less than or equal to 2 cm, as “intermediate pneumothorax”; greater than 2 cm, symptomatic or chest drainage catheter insertion needed, as “severe pneumothorax” [12].

**CT-guided core needle biopsy**

PCNBs were performed by one intervention team led by Prof. C. L. (7 years of experience in CT-guided needle biopsy), using only one type of needle, 17-gauge coaxial introducer and 18-gauge automated cutting needle (Biopince, Argon Medical Devices, Frisco, Texas). All the biopsies were carried out according to the standard protocol. All patients underwent enhanced CT before the biopsy. Averting obvious emphysema or bulla, the safest and shortest route from the chest wall to solid part of the lesion was chosen to determine the supine, prone or lateral position of the patient on the CT table. All patients were given intravenous indwelling needles, allowing for the infusion of rescue drugs if necessary. The patients were instructed to breathe shallowly and avoid moving, coughing, speaking or deep breathing during and 3 h after the procedure. If the biopsy route needed to be changed, the patient’s position could also be changed. After aseptic technique and local anesthesia with 1% lidocaine, the introducer needle was inserted. The needle is inserted rapidly during pleural puncture, and the needle is withdrawn slowly after the biopsy. Rapid insertion at breath-hold can form a precise puncture point, while slow extraction of the guide needle can make the elastic lung tissue seal the pleural hole. Then the position of the coaxial introducer was determined by CT scan. If the introducer was correctly located within the periphery...
of the lesion, the biopsy was performed to obtain sufficient tissue samples. The representative images of the CT-guided PCNB are shown in Fig. 1. After slowly removing the needle, CT scan was performed to evaluate the complications. The patient was then asked to rest for 24 h. Patients with pneumothorax or bleeding were monitored in the inpatient ward. Patients with intermediate or severe pneumothorax were arranged to have a follow-up CT scan to determine its stability. If patients had pneumothorax with symptoms of respiratory distress or shortness of breath, a closed thoracic drainage (8 Fr. pig-tail) was performed.

Pulmonary function test

All patients were selected who received pulmonary function tests within 7 days before CT-guided PCNBs, in one single center of Qilu Hospital. According to the pulmonary function test, as well as their illnesses and severity, patients were mainly classified into groups of normal, small airway dysfunction, obstructive, restrictive and mixed pulmonary function abnormalities [13]. The judgment processes of pulmonary function abnormalities were referred to previous studies [13–15]. Forced expiratory volume in one second (FEV₁)/forced vital capacity (FVC) ratio and FVC should be considered first [13, 14]. Obstructive abnormality is defined as a fixed ratio of FEV₁/FVC < 70% [14]. Restrictive abnormality is characterized by a normal FEV₁/FVC and a reduction in FVC [14, 15]. A mixed pulmonary function abnormality is characterized by the coexistence of obstruction and restriction.

Conventional ventilation function parameters such as FEV₁, FEV₁/FVC and FVC were still in the normal range, but two of these three parameters FEF₅₀%, FEF₇₅% and FEF₂₅–₇₅% were lower than 65% of the predicted value, which can be diagnosed as small airway dysfunction [15].

Statistical analysis

After CT-guided lung biopsy, the patients were divided into two groups with or without pneumothorax. Clinical data contained characteristics associated with demographics, lesion, technique, diagnosis and pulmonary function. All quantitative data were non-normally distributed by the Shapiro–Wilk test. The Mann–Whitney U test was used for quantitative variables with non-normal distribution. The chi-square test was used to test the categorical variables. For small samples (n < 5), the Fisher exact test was used. Multivariate logistic regression analysis was used to identify the independent predictor of pneumothorax. Logistic regression model only contained significant covariates from univariate analysis. The variance inflation factor (VIF) was applied to measure multicollinearity. A VIF between 5 and 10 indicated
high correlation that may be problematic. A two-tailed $P$ value $<0.05$ was defined as significant different. All statistical tests were performed by SPSS software package, standard Version 17.0 (SPSS Inc., Chicago, IL, USA).

**Results**

**Comparison of groups with and without pneumothorax evaluated by univariate analysis**

There were 206 (60.1%) male and 137 (39.9%) female patients in this study. Only two patients received prior chemotherapy, one received prior thoracic surgery, and no one received prior thoracic radiotherapy. The baseline characteristics of these 343 patients were summarized in Table 1. All the quantitative data showed non-normal distribution, so the median and the inter-quartile range (IQR) were presented here. The median age was 62 years (range 18–82 years) and the median depth from the pleura to the lesion was 11.6 mm (range 0–70.3 mm). The diameter of the lesions punctured varied from 6.8 to 212.1 mm, with a median of 26.7 mm in previous CT images. The median needle-pleural angle was measured to be 65° (range 0–90°). The median dwell time was 200 s (range 70–1200 s). Pathologically, the 248 (72.3%) malignant diagnosis mainly included 191 (55.7%) adenocarcinomas, 34 (9.9%) squamous cell carcinomas, 6 (1.7%) small cell carcinomas, and 6 (1.7%) metastases from other tumor sites (Table 2). In 80 (23.3%) benign pulmonary lesions, 71 (20.7%) were assessed as chronic pneumonia. In addition, there were 2 (0.6%) patients with borderline tumor. There were still 13 (3.8%) cases without histopathologic results for inadequate tissue sampling. Thus, primary diagnostic yield of CT-guided PCNB was 96.2%.

The main complications of PCNBs were pneumothorax, chest drainage catheter insertion and intrapulmonary hemorrhage. Fifty patients (14.6%) had pneumothorax after PCNBs. Among those, only three patients (6.0%) revealed severe pneumothorax on post-biopsy CT scans, which required placement of chest drainage catheter. In the most serious case of pneumothorax, the lung was compressed by 1/3. All patients with mild or moderate pneumothorax were stable without deterioration and any interventional treatment. Of all the 343 patients, 88 (25.7%) had intrapulmonary hemorrhage, most of which were slight hemorrhage.

The differences in clinical characteristics between groups with and without pneumothorax were evaluated by univariate analysis (Table 1). Variables associated with higher rate of pneumothorax were lower location ($P = 0.004$), presence of emphysema ($P = 4.929 \times 10^{-8}$), and dwell time ($P = 0.046$), whereas all the other parameters including demographic and diagnostic parameters showed nonsignificant findings. As shown, the proportion of lower locations in pneumothorax group (30/50, 60.0%) is higher than non-pneumothorax group (113/293, 38.6%). The dwell time varied from 70 to 1200 s, with a median of 240 s in patients with pneumothorax and 200 s in patients without pneumothorax. The incidence of emphysema in pneumothorax group was significantly higher than that in non-pneumothorax group (34.0% vs. 7.5%). However, other possible risk factors about lesion and technique, previously reported, such as lesion size, adjacent pleura, length of intrapulmonary needle tract, needle-pleural angle, and number of pleural punctures, showed no statistically significance of pneumothorax in this study.

**Differences in pulmonary function between groups with and without pneumothorax evaluated by univariate analysis**

On the other hand, the pulmonary function of these 343 patients was also evaluated (Table 3). The main pulmonary function parameters were as follows: FVC(% pred) 103.3% (92.0–115.5%), FEV1(% pred) 98.0% (81.7–109.9%), FEV1/FVC ratio 76.0% (69.1–81.2%), FEF25–75%(% pred) 58.0% (37.4–78.6%) and peak expiratory flow (PEF% pred) 104.4% (84.4–119.6%).

Furthermore, there was statistically significant difference of pulmonary function parameters between the two groups with or without pneumothorax as expressed by FEV1/FVC ratio ($P = 0.004$), FEF50%(% pred) ($P = 0.014$), FEF75%(% pred) ($P = 0.037$), and FEF25–75%(% pred) ($P = 0.033$). No difference was found in FVC between the two groups. And more importantly, as seen in Table 3, although FEV1 was not significantly different between the two groups of patients, FEV1/FVC ratio was significantly lower in patients with pneumothorax (median with IQR: 72.5, 67.1–78.4) than without pneumothorax (76.6, 69.8–81.5). Interestingly, as no other research has been studied so far, the small airway function parameters, such as FEF50%, FEF75% and FEF25–75%, showed significant negative correlations with pneumothorax rate. However, maximum voluntary ventilation (MVV), PEF and FEF25%, which reflect the large airway function, were not associated with the risk of pneumothorax.

**Relationship between incidence of pneumothorax and pulmonary function abnormalities**

Patients with pneumothorax had much lower FEV1/FVC ratio than those without pneumothorax, as shown above, indicating that patients with obstructive diseases were more likely to have pneumothorax. Table 4 shows the relationship between pulmonary function abnormalities and pneumothorax. The chi-square test revealed that obstructive pulmonary function abnormalities, as assessed by a decrease in FEV1/FVC ratio,
**Table 1** Comparison of groups with and without pneumothorax evaluated by univariate analysis

| Clinical characteristics | All patients studied | Pneumothorax | *X²/Z* | *P Value* \( ^{†} \) |
|---------------------------|----------------------|--------------|--------|----------------------|
| **No. of cases analyzed** | 343                  | 50 (14.6%)   | 293 (85.4%) |                      |
| **Demographic characteristic** |                       |              |        |                      |
| Age (years)               | 62 (53–68)           | 61 (55–65)   | 62 (53–68) | 0.558 0.577          |
| Gender                    |                       |              |        |                      |
| Male                      | 206 (60.1%)          | 34 (9.9%)    | 172 (50.1%) | 1.539 0.215          |
| Female                    | 137 (39.9%)          | 16 (4.7%)    | 121 (35.3%) |                      |
| Pack-years smoking        | 0 (0–30)             | 6 (0–30)     | 0 (0–30)  | 0.752 0.452          |
| **Lesion characteristics** |                       |              |        |                      |
| Location of lesion        | 8.071 0.004          |              |        |                      |
| Upper                     | 200 (58.3%)          | 20 (5.8%)    | 180 (52.5%) |                      |
| Lower                     | 143 (41.7%)          | 30 (8.8%)    | 113 (32.9%) |                      |
| Lesion size (mm)          | 108 (31.49%)         | 11 (3.2%)    | 97 (28.3%) | 2.442 0.118          |
| < 20                      | 235 (68.51%)         | 39 (11.4%)   | 196 (57.1%) |                      |
| ≥ 20                      |                       |              |        |                      |
| Adjacent pleura or chest wall invasion | 0.057 0.812 | 29.744 4.929 x 10^-8 | |
| Yes                       | 211 (61.5%)          | 30 (8.8%)    | 181 (52.8%) |                      |
| No                        | 132 (38.5%)          | 20 (5.8%)    | 112 (32.6%) |                      |
| Presence of emphysema     |                       |              |        |                      |
| Yes                       | 39 (11.4%)           | 17 (5.0%)    | 22 (6.4%) | 29.744 4.929 x 10^-8 |
| No                        | 304 (88.6%)          | 33 (9.6%)    | 271 (79.0%) |                      |
| **Technique characteristics** |                       |              |        |                      |
| Patient position          | 1.619 0.445          |              |        |                      |
| Supine                    | 104 (30.3%)          | 13 (3.8%)    | 91 (26.5%) |                      |
| Prone                     | 192 (56.0%)          | 32 (9.3%)    | 160 (46.7%) |                      |
| Lateral decubitus         | 47 (13.7%)           | 5 (1.5%)     | 42 (12.2%) |                      |
| Needle puncture site      | 1.559 0.816          |              |        |                      |
| Anterior                  | 42 (12.2%)           | 7 (2.0%)     | 35 (10.2%) |                      |
| Anterolateral             | 54 (15.8%)           | 6 (1.7%)     | 48 (14.0%) |                      |
| Lateral                   | 37 (10.8%)           | 5 (1.5%)     | 32 (9.3%) |                      |
| Posterior                 | 165 (48.1%)          | 27 (7.9%)    | 138 (40.2%) |                      |
| Posterolateral            | 45 (13.1%)           | 5 (1.5%)     | 40 (11.7%) |                      |
| Length of intrapulmonary needle tract (mm) | 11.6 (0.0–19.9) | 11.0 (0.0–21.8) | 11.6 (0.0–19.9) | -0.405 0.685 |
| Dwell time (s)            | 200 (169–283)        | 240 (174–360) | 200 (168–271) | -1.992 0.046 |
| Needle-pleural angle (°)  | 65 (48–80)           | 69 (52–85)   | 63 (48–80)  | -1.078 0.281          |
| Needle redirections       | 1.118 0.290          |              |        |                      |
| Yes                       | 31 (9.0%)            | 7 (2.0%)     | 24 (7.0%) |                      |
| No                        | 312 (91.0%)          | 43 (12.5%)   | 269 (78.4%) |                      |
| No. of pleural punctures  | 1 (1–1)              | 1 (1–1)      | 1 (1–1)   | -0.492 0.622          |
| No. of cores              | 2 (1–2)              | 2 (2–3)      | 2 (1–2)   | -1.014 0.311          |
| Diagnostic characteristics |                       |              |        |                      |
| Malignant                 | 248 (72.3%)          | 40 (11.7%)   | 208 (60.6%) |                      |
| Benign                    | 80 (22.3%)           | 9 (2.6%)     | 71 (20.7%) |                      |
| Borderline                | 2 (0.6%)             | 0            | 2 (0.6%) |                      |
| Non-diagnostic/inadequate | 13 (3.8%)            | 1 (0.3%)     | 12 (3.5%) |                      |

**Significant difference (P<0.05) are shown in bold**

* Data are shown as number N (%) for categorical variables or median (lower quartile to upper quartile) for quantitative variables with non-normal distribution

† Chi-square test for categorical variables. Mann–Whitney U test for quantitative variables. All quantitative data showed non-normal distribution by Shapiro–Wilk test

\(^6\) Range only for quantitative variables
were associated with a higher incidence of pneumothorax (\(P=0.005\)). The incidence of pneumothorax in the obstructive ventilation abnormalities was 24.7%, whereas in the normal group the rate dropped to 10.7%. The restrictive and mixed ventilation function abnormalities were not found to correlate with the pneumothorax rate (\(P=1.000\) and \(P=0.961\), respectively).

In addition, the incidence of pneumothorax was not significantly different between patients with small airway dysfunction and patients with normal ventilation function (\(P=0.413\)).

### Multivariable logistic regression model for predictors of pneumothorax in all patients studied

Multivariate logistic regression analysis was used to identify the independent predictor of pneumothorax (Table 5). Here, the analysis only considered covariables significant by univariate analysis mentioned in Tables 1 and 3. VIFs for these variables showed no multicollinearity. Lower location of lesion sampled and presence of emphysema were identified to be independent predictors of pneumothorax after CT-guided PCNB (\(P=0.021\) and \(P=8.700 \times 10^{-5}\), respectively). In all patients, risk of pneumothorax was significantly higher in lower location of lesion sampled (odds ratio [OR], 2.150; 95% confidence interval [CI] 1.124–4.113) and presence of emphysema (OR, 5.217; 95% CI 2.286–11.901). Although dwell time, \(\text{FEV}_1/\text{FVC}\) ratio, \(\text{FEF}_{50\%}\), \(\text{FEF}_{75\%}\) and \(\text{FEF}_{25–75\%}\) were significantly correlated with pneumothorax on univariate analysis, these were not confirmed to be independent risk factors here.

### Discussion

The CT-guided pulmonary PCNB can biopsy smaller pulmonary nodules with the progress of technology, but pneumothorax is still one of the most frequent complications. The rate of pneumothorax induced by PCNB was

---

**Table 2** Pathological types after CT guided lung puncture (343 cases)

| Diagnostic characteristics | N (%)     |
|---------------------------|-----------|
| Malignant                 | 248 (72.3%) |
| Adenocarcinoma            | 191 (55.7%) |
| Squamous cell carcinoma   | 34 (9.9%)  |
| Small cell carcinoma      | 6 (1.7%)   |
| Metastasis from other tumor sites | 6 (1.7%) |
| Neuroendocrine tumor      | 4 (1.2%)   |
| Malignant pleural mesothelioma | 3 (0.9%) |
| Undifferentiated carcinoma| 2 (0.6%)   |
| Adenosquamous carcinoma   | 1 (0.3%)   |
| Lymphoepithelioid carcinoma| 1 (0.3%) |
| Benign                    | 80 (23.3%) |
| Chronic pneumonia         | 71 (20.7%) |
| Alveolitis                | 2 (0.6%)   |
| Pulmonary hamartoma       | 2 (0.6%)   |
| Tuberculosis              | 2 (0.6%)   |
| Sclerosing pneumocytoma   | 2 (0.6%)   |
| Neurilemmoma              | 1 (0.3%)   |
| Borderline                | 2 (0.6%)   |
| Solitary fibrous tumor    | 1 (0.3%)   |
| Inflammatory myofibroblastic tumor | 1 (0.3%) |
| Non-diagnostic/inadequate| 13 (3.8%)  |

---

**Table 3** Differences in pulmonary function between groups with and without pneumothorax evaluated by univariate analysis*

| Clinical characteristics | All patients studied | Pneumothorax | Z   | P Value† |
|--------------------------|----------------------|--------------|-----|---------|
|                          | Median               | Lower quartile – upper quartile | Yes* | No*     |       |
| No. of cases analyzed    | 343                  | 50 (14.6%)  | 293 (85.4%)  | −0.363 | 0.716 |
| Pulmonary function characteristics | | | | | |
| FVC (% pred)             | 103.3                | 92.0–115.5   | 105.0 (93.3–114.8) | 103.0 (91.6–115.7) | −0.363 | 0.716 |
| FEV\(_1\) (L)            | 2.4                  | 2.0–2.9      | 2.4 (1.9–2.7) | 2.4 (2.0–3.0) | −0.700 | 0.484 |
| FEV\(_1\) (% pred)       | 98.0                 | 81.7–109.9   | 94.8 (79.4–106.8) | 98.4 (82.0–110.1) | −1.101 | 0.271 |
| FEV\(_1\)/FVC ratio (%) | 76.0                 | 69.1–81.2    | 72.5 (67.1–78.4) | 76.6 (69.8–81.5) | −2.897 | 0.004 |
| FEF\(_25\%\) (% pred)   | 88.4                 | 64.0–106.1   | 73.5 (56.5–102.5) | 89.5 (66.6–106.5) | −1.950 | 0.051 |
| FEF\(_50\%\) (% pred)   | 72.8                 | 48.9–94.6    | 58.5 (39.8–84.5) | 77.5 (51.7–95.9) | −2.458 | 0.014 |
| FEF\(_75\%\) (% pred)   | 66.4                 | 44.7–89.9    | 55.7 (42.1–79.4) | 70.5 (45.4–91.1) | −2.085 | 0.037 |
| FEF\(_25–75\%\) (% pred) | 58.0                | 37.4–78.6    | 44.3 (30.0–66.3) | 59.6 (39.4–79.8) | −2.134 | 0.033 |
| PEF (% pred)             | 104.4                | 84.4–119.6   | 101.5 (83.2–114.7) | 104.5 (85.0–121.0) | −1.253 | 0.210 |
| MVV (% pred)             | 95.7                 | 83.3–111.9   | 96.4 (83.6–109.2) | 95.5 (83.2–112.7) | −0.382 | 0.703 |

Significant difference (\(P<0.05\)) are shown in bold

* Data are shown as median (lower quartile to upper quartile)

† Mann–Whitney U test. All the quantitative data showed non-normal distribution by Shapiro–Wilk test
14.6% in this study, and that of chest tube placement was 0.9%, which were similar to the rates reported in other studies [9, 16, 17]. In order to explore the risk factors of pneumothorax, clinical data such as patient demographics, characteristics of target lesions, procedure-related information, the histopathological diagnosis and results of pulmonary function test were all collected here. However, patient-related and diagnosis-related predictors had no influence on the occurrence of pneumothorax. Interestingly, Ko et al. [6] reported that pneumothorax was unlikely to occur in patients who had prior thoracic surgery, focal or diffuse pleural disease, or chest wall involvement. However, few patients in our study had prior thoracic surgery, which might contribute to the inconsistency.

Concerning lesion characteristics in this study, several predictors influenced the incidence of pneumothorax, such as the location of lesion and the presence of emphysema. Emphysema as a risk factor for pneumothorax was reported [7], but there was also different opinion [18]. Asai et al. [18] found that severity of emphysema such as stage I or II COPD, or high scores of low attenuation area (LAA) by Goddard classification were not be related to the frequency of pneumothorax. However, severe and very severe COPD patients (stage III and IV) were not included in that study. Selection bias might exist. No association was found between the incidence of pneumothorax and the depth, the size of the lesion and the invasion of adjacent pleura or chest wall, which were former risk factors for pneumothorax [5, 11, 17, 19–24]. PCNB replaced FNAB with technological advancement. For instance, several studies suggested that smaller lesion size increased the risk of pneumothorax in FNAB [17], while others found that they did not in PCNB [24]. This may be related to the increased numbers of punctures in smaller lesions with FNAB. The incidence of pneumothorax increased 2 times (66% vs. 32%) when the depth of lesion was larger than 2.0 cm, partly due to the prolongation of dwell time and the increased amount of lung tissues that the needle penetrates [17]. However, other studies on the depth of lesions and pneumothorax were quite opposite. Some studies thought that the lesion adjacent pleura or chest wall invasion was more prone to pneumothorax. Yeow et al. [24] reported that when the subpleural lesions were within 2 cm below the pleural surface, the risk of pneumothorax was sevenfold higher than the lesion depth more than 2 cm. They explained that subpleural lesions tend to shift the needle into the pleural cavity, causing air to enter [24]. We did not observe the similar phenomenon, probably because we used oblique needle approach to deal with the lesions abut pleura.

In terms of procedure-related factors, dwell time was significantly correlated with pneumothorax on univariate analysis.
analysis, but it was not confirmed as an independent predictor in logistic regression model here. The longer time the needle dwelled in the lung, the more likely the respiratory movement would cause the lung to be punctured. There are both consistent and inconsistent studies [6, 7]. The dwell time span of this study was large (from 70 to 1200 s), so the effect of dwell time on pneumothorax could be better observed. Dwell time was not an independent factor, probably because it was also affected by the lung tissue structure near the needle tract and the presence or absence of emphysema. Several studies [5, 6] reported that patients with needle-pleural angles less than 80° and, in particular, less than 50°, had a higher risk of pneumothorax. However, we did not observe any impact of needle-pleural angle on complication rate of CT-guided PCNB. The negative correlation between needle-pleural angle and pneumothorax was not only due to the prolongation of intrapulmonary needle tract, but also due to the enlargement of pleural foramen torn by the needle passage [6]. The shape of the pleural aperture increased the amount of air leaking from the lung [25]. We analyzed that the reason we did not find the correlation was because we deliberately avoided oblique needle puncture in clinical practice. We have been willing to sacrifice the risk of changing the needle puncture site or prolonging the intrapulmonary needle tract in order to make the needle as perpendicular to the pleura as possible (median with IQR: 65°, 48°–80°).

Patients with obstructive pulmonary function abnormalities were at greater risk for PCNB-induced pneumothorax, which was consistent with other studies [11]. For patients with severe impairment of pulmonary function, clinicians are usually reluctant to use core needle biopsy for fear of continuous air leakage. In order to derive a quantitative index of risk for pneumothorax, pulmonary function characteristics were evaluated here. The pulmonary function index to predict PCNB-induced pneumothorax included: FEV₁% pred, FEV₁/FVC ratio, FVC% pred, FEF₂₅₋₇₅% (which was effort-dependent) [6, 9, 11].

However, some of these factors are inconsistent. Here, FEV₁/FVC ratio was found to be most strongly associated with pneumothorax, which was in accordance to previous reports [6, 16, 17]. However, there were some controversies in the literature about the correlation between the abnormal pulmonary function analysis and the incidence of pneumothorax. In a retrospective analysis of 243 patients, Vitulo et al. [9] reported that no predictive value for pneumothorax was found in pulmonary function test. Several authors [6, 16–19] revealed a significant relationship between pneumothorax and FEV₁% pred. Garcia-Rio et al. [16] found FEV₁% pred, FVC% pred, FEV₁/FVC ratio were significantly lower in patients with pneumothorax, and the closest correlation being with FEV₁ % pred. But our results were contrary to the observations of these studies. No difference was found in FEV₁% pred between the two groups here.

Patients with obstructive functional abnormalities had significantly higher incidence of pneumothorax than those with normal or other types of pulmonary abnormalities. The increase in pneumothorax was due to poor lung elasticity, reduced alveolar air retraction, rupture of the expanded alveoli, emphysema along the needle tract and difficulty in holding breath [11, 17]. Narrowing and disappearance of small airways before the onset of emphysematous destruction can be found in COPD [26]. This might provide explanation of small airway obstruction with hyperinflation is consistent risk in many reports but emphysema is not.

Furthermore, in this study, FEF₅₀%, FEF₇₅% and FEF₂₅₋₇₅% are significantly negatively correlated with the incidence of pneumothorax. Other lung function parameters such as FVC, FEV₂₅% and PEF showed no statistical difference. This study is unique because so far, no other research paper has analyzed such detailed lung function predictors for pneumothorax. FEF₅₀%, FEF₇₅% and FEF₂₅₋₇₅% are the middle and end expiratory indexes of exertion dependence, which reflect small airway ventilation function. Small airway dysfunction refers to the dysfunction caused by infection, smoking and external environment in the airway with a diameter of less than 2 mm, including both small bronchi and proximal bronchioles. Small airways are known as one of the major sites of airflow obstruction in chronic obstructive pulmonary diseases (COPDs). Even before the destruction of emphysema, the narrowing and disappearance of small airways can be observed in patients with obstructive functional abnormalities, leading to the increase of peripheral airway resistance [26]. Small airway dysfunction is a common but easily ignored lung dysfunction, long known as the silent zone of the lung. Small airway lesions are characterized by smooth muscle hyperplasia and hypertrophy, inflammatory cells including neutrophils and macrophages increasing, goblet cell hyperplasia, mucus hypersecretion and obstruction, airway wall thickening and fibrosis [26]. As a result, the airflow is restricted, the alveoli are overinflated, the alveolar attachment of the small airways is destroyed, the elastic retraction of lung is reduced, and the internal pressure of the alveoli increases, thereby increasing the occurrence of pneumothorax [14, 27]. Interestingly, in this study, small airway function parameters FEF₅₀%, FEF₇₅% and FEF₂₅₋₇₅% showed significant negative correlations with pneumothorax rate (Table 3). However, no significant correlation was found between small airway dysfunction and pneumothorax (Table 4). This was mainly because small
airway function indicators were significantly reduced not only in small airway dysfunction group, but also in obstructive functional abnormalities group (Additional file 1: Table S1). Therefore, logistic regression analysis was further employed to evaluate the roles of pulmonary function parameters in the risk of pneumothorax, respectively (Table 5). Although FEV$_1$/FVC ratio significantly correlated with pneumothorax on univariate analysis, multivariate logistic regression analysis showed no statistical significance. This indicates that FEV$_1$/FVC is not an independent predictor, and may be related to other factors.

This study had several limitations. CT-guided PCNB studied here were all performed by one intervention team with only one type of needle according to the standard protocol. Some factors demonstrated no statistical significance here, which does not mean that they have nothing to do with pneumothorax. This may be due to the standardization of the procedures. Ko et al. [6] indicated that pneumothorax more commonly occurred in patients with lesions adjacent pleura or invading the chest wall. However, our puncture approach was deliberately avoided the fissure. Hence, no statistical significance of this factor was found. We used only one size of biopsy needle in this study, making it impossible to compare different sizes of the biopsy specimens. In addition, selection bias might exist. The patients studied here mainly had milder obstructive ventilatory impairment (median FEV$_1$% pred 98.0% with IQR 81.7–109.9%, and median FEV$_1$/ FVC 76.0% with IQR 69.1–81.2%). These populations were thought to be relatively safe for PCNB and might influence the results. Furthermore, the limited reliability of this study on the risk for pneumothorax in restrictive and mixed ventilation abnormalities may be due to the limited number of such patients.

Conclusions
Patients with obstructive pulmonary dysfunction have a higher risk of pneumothorax. Presence of emphysema was the most important predictor of pneumothorax, followed by location of lesion.

Abbreviations
COPD: Chronic obstructive pulmonary disease; CT: Computed tomography; FEF$_{25-75}$: Mean forced expiratory flow between 25 and 75% of FVC; FEF$_{50}$: Instantaneous forced expiratory flow when 50% of the FVC has been expired; FEV$_1$: Forced expiratory volume in one second; FNAB: Fine needle aspiration biopsy; FVC: Forced vital capacity; LLN: Lower limits of normal; MVV: Maximum voluntary ventilation; OR: Odds ratio; PEF: Peak expiratory flow; PCNB: Percutaneous core needle biopsy; % pred: Percent of predicted.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12890-021-01625-0.

Acknowledgements
The authors thank Xubin Sun (Public Health Institute, Cheeleeo College of Medicine, Shandong University) for his support in Epidemiological statistics, and here we declare that no payment was received for this study.

Authors’ contributions
CHL and WZ designed the experiments. WZ supervised the study. CHL, DXW, FXY, YS and WZ performed the experiments. XJY, BL and HPJ assisted with the performance of experiments. CHL, WDX and WZ analyzed the data. CHL and WZ wrote the paper. All authors read and approved the final manuscript.

Funding
This work was supported by Shandong Provincial Key Research and Development Program (2018GSF118087).

Availability of data and materials
All data generated and analyzed during the current study are included in this published article.

Declarations
Ethics approval and consent to participate
All procedures performed were in accordance with the Declaration of Helsinki and the study was approved by The Institutional Ethics and Investigation Committee of Qilu Hospital, Shandong University [approval no. KYLL-202008-145]. All patients provided informed written consent.

Consent for publication
Not Applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Radiology, Qilu Hospital, Cheeleeo College of Medicine, Shandong University, 107 Wenhuaxi Road, Jinan 250012, Shandong, China. 2 Department of Respiratory Medicine, Qilu Hospital, Cheeleeo College of Medicine, Shandong University, 107 Wenhuaxi University, Jinan 250012, Shandong, China. 3 Department of Radiation Oncology, Qilu Hospital, Cheeleeo College of Medicine, Shandong University, 107 Wenhuaxi Road, Jinan 250012, Shandong Province, China.

Accepted: 3 August 2021
Published online: 06 August 2021

References
1. Heerink WI, de Bock GH, de Jonge CJ, Groen JJ, Viegenthart R, Oudkerk M. Complication rates of CT-guided transthoracic lung biopsy: meta-analysis. Eur Radiol. 2017;27:138–48.
2. Minot DM, Gilman EA, Aubry MC, Voss JS, Van Epps SG, Tuve DJ, Sciallis AP, Henry MR, Salomao DR, Lee P, Carlson SK, Clayton AC. An investigation into false-negative transthoracic fine needle aspiration and core biopsy specimens. Diagn Cytopathol. 2014;42:1063–8.
3. Hong YJ, Hur J, Lee HJ, Nam JE, Kim YJ, Kim HS, Kim HY, Kim SK, Chang J, Kim JH, Chung KY, Choi BW, Choe KO. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle
aspiration biopsy for the diagnosis of non-small cell lung cancer. J Thorac Oncol. 2011;6:1330–5.

4. Solomon SB, Zakowski MF, Pao W, Thornton RH, Ladanyi M, Kris MG, Rusch VW, Rizvi NA. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutation analysis. AJR Am J Roentgenol. 2010;194:266–9.

5. Saji H, Nakamura H, Tsuchida T, Tsuibo M, Kawate N, Konaka C, Kato H. The incidence and the risk of pneumothorax and chest tube placement after percutaneous CT-guided lung biopsy: the angle of the needle trajectory is a novel predictor. Chest. 2002;121:1521–6.

6. Ko JP, Shepard JO, Drucker EA, Aquino SL, Sharma A, Sabloff B, Halpern E, McCloud TC. Factors influencing pneumothorax rate at lung biopsy. Are dwell time and angle of pleural puncture contributing factors? Radiology. 2001;218:491–6.

7. Rued EA, Stavem K, Geitung JT, Borthne A, Soyseth V, Ashraf H. Predictors of pneumothorax and chest drainage after percutaneous CT-guided lung biopsy: A prospective study. Eur Radiol. 2021;31:4243–52.

8. Ashraf H, Krag-Andersen S, Naqibullah M, Minddal V, Norgaard A, Naur TMH, Myschetzky PS, Clementsen PF. Computer tomography guided lung biopsy using interactive breath-hold control: a randomized study. Ann Transl Med. 2017;5:253.

9. Vitulo P, Dore R, Cerveri I, Tinelli C, Cremaschi P. The role of functional respiratory tests in predicting pneumothorax during lung needle biopsy. Chest. 1996;109:612–5.

10. Drumm O, Joyce EA, de Blacam C, Gleeson T, Kavanagh J, McCarthy E, McDermott R, Beddy P. CT-guided lung biopsy: effect of biopsy-side down position on pneumothorax and chest tube placement. Radiology. 2019;292:190–6.

11. Olkononou A, Matzinger FR, Seely JM, Dennie CJ, Macleod PJ. Ultrathin needle (25 G) aspiration lung biopsy: diagnostic accuracy and complication rates. Eur Radiol. 2004;14:375–82.

12. Nikolic MZ, Lok LS, Mattishent K, Barth S, Yung B, Cummings NM, Wade D, Vali Y, Chong K, Wilkinson A, Mikolasch T, Brij S, Jenkins HS, Kamath AV, Pasteur M, Hopkins TG, Wason J, Marciniak SJ. Noninterventional statistical comparison of BTS and CHEST guidelines for size and severity in primary pneumothorax. Eur Respir J. 2015;45:1731–4.

13. Pellegrino R, zakowski MF, Pao W, Thornton RH, Ladanyi M, Kris MG, Rusch VW, Rizvi NA. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutation analysis. AJR Am J Roentgenol. 2010;194:266–9.

14. Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, Agusti AA, Vogelmeier CF, Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD science committee report on COPD-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203:24–36.

15. Ruppel GL, Enright PL. Pulmonary function testing. Respir Care. 2012;57:165–75.

16. Garcia-Rio F, Pino JM, Casadevall J, Gomez L, Atenza JM, Diaz-Lobato S, Villamor J. Use of spirometry to predict risk of pneumothorax in CT-guided needle biopsy of the lung. J Comput Assist Tomogr. 1996;20:20–3.

17. Kazerooni EA, Lim FT, Mikhail A, Martinez FJ. Risk of pneumothorax in CT-guided transthoracic needle aspiration biopsy of the lung. Radiology. 1996;198:371–5.

18. Asai N, Kawamura Y, Yamazaki I, Sogawa K, Ohkuni Y, O’uchi T, Kubo A, Yamaguchi E, Kaneko N. Is emphysema a risk factor for pneumothorax in CT-guided lung biopsy? Springerplus. 2013;2:196.

19. Heyer CM, Reichelt S, Peters SA, Walther JW, Muller KM, Nicolas V. Computed tomography-navigated transthoracic core biopsy of pulmonary lesions: Which factors affect diagnostic yield and complication rates? Acad Radiol. 2008;15:1017–26.

20. Otto S, Mensel B, Friedrich N, Schafer S, Mahlke C, von Bernstorff W, Bock K, Hosten N, Kuhn JP. Predictors of technical success and rate of complications of image-guided percutaneous transthoracic lung needle biopsy of pulmonary tumors. PLoS ONE. 2015;10:947.

21. Taleb S, Jaleaen H, Frank N, Golzarian J, O’Souza D. Is a routine chest X-ray necessary in every patient after percutaneous CT-guided lung biopsies? A retrospective review of 278 cases. Cardiovasc Intervent Radiol. 2017;40:1415–20.

22. Cheung YC, Chang JW, Hsieh JJ, Lin G, Tsai YH. Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle. Lung Cancer. 2010;67:166–9.

23. Li H, Boiselle PM, Shepard JO, Trotman-Dickenson B, McCloud TC. Diagnostic accuracy and safety of CT-guided percutaneous needle aspiration biopsy of the lung: comparison of small and large pulmonary nodules. AJR Am J Roentgenol. 1996;167:105–9.

24. Yeow KM, See LC, Lui KW, Lin MC, Tsao TC, Ng KF, Liu HP. Risk factors for pneumothorax and bleeding after CT-guided percutaneous coaxial cutting needle biopsy of lung lesions. J Vasc Interv Radiol. 2001;12:1305–12.

25. Moore EH. Technical aspects of needle aspiration lung biopsy: a personal perspective. Radiology. 1998;208:303–18.

26. Day K, Ostridge K, Conway J, Cellura D, Watson A, Spalluto CM, Staples TMH, Myschetzky PS, Clementsen PF. Computer tomography guided lung biopsy: A prospective study. Eur Radiol. 2021;31:4243–52.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.